Latest news for Odyssey Semiconductor (OTC:ODII) Stock

Odyssey Semiconductor Technologies Inc is a semiconductor device company developing revolutionary high-voltage power switching components and systems based on proprietary Gallium Nitride (GaN) processing technology. The company's GaN processing technology allows for the realization of vertical current conduction GaN devices which extends application voltages from 1,000 V to over 10,000V, allowing GaN power switching devices to extend well beyond the consumer electronics application space and into more demanding applications such as electric vehicles, industrial motor control, and energy grid applications.

ODYSSEY SEMCONDCTR TECH by Odyssey Semiconductor Technologies Inc.

Odyssey Semiconductor Technologies Inc

Macquarie analyst Ellie Jiang initiates coverage on DiDi Global (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DIDIY#OTC">DIDIY</a>) with a Outperform rating and announces Price Target of $5.5.

News

Price Target

Initiation

Analyst Ratings

DIDI GLOBAL INC S/ADR by DiDi Global Inc.

DIDIY

Macquarie Initiates Coverage On DiDi Global with Outperform Rating, Announces Price Target of $5.5

BCLI

BrainStorm Cell Therapeutics Plans To Share Latest Update On NurOwn At This Year's NEALS Meeting

Catalyst Pharmaceuticals, Inc.&nbsp;("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE&#xAE; (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
"We are pleased that our partner, DyDo, has secured regulatory approval for FIRDAPSE in Japan. This represents a meaningful milestone, bringing renewed hope to patients and further affirming FIRDAPSE's proven effectiveness in the treatment of LEMS," said Richard J. Daly, Catalyst's President and Chief Executive Officer. "This achievement underscores our unwavering commitment to advancing patient care. We appreciate the collaborative efforts of our partner in securing this approval, and we remain focused on expanding our innovative rare disease product portfolio beyond the U.S. to make a meaningful impact on patients' lives worldwide."
FIRDAPSE (amifampridine) is a leading therapy indicated in the United States for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. About 50% of people with LEMS have underlying cancer, as LEMS is observed in approximately 3% of small-cell lung cancer patients. FIRDAPSE is the only U.S. FDA-approved, evidence-based treatment for LEMS. As a cornerstone of Catalyst's commitment to serving those with rare diseases, FIRDAPSE is supported in the U.S. by a comprehensive patient support program to help ensure accessibility and assistance for eligible U.S. patients.

Government

Regulations

CPRX

Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")

Buybacks

ARLO

Arlo Technologies Plans Repurchase Of Up To An Aggregate Of $50M Of Shares Of Its Common Stock

The application to the PMDA was based on the efficacy and safety data from TRAILBLAZER-ALZ 2 Phase 3 clinical study.

Eli Lilly Says Japan Has Approved Kisunla (Donanemab-azbt, 350 Mg/20 mL Every Four Weeks Injection For IV Infusion) For Early Symptomatic Alzheimer's Disease

Revelation Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews73&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=topline+data+from+the+Phase+1+clinical+study+of+Gemini&amp;index=1&amp;md5=251ba51b272b745c89d17af8755c3483">topline data from the Phase 1 clinical study of Gemini</a> released on June 24, 2024.
Using high sensitivity serum IL-10 biomarker analysis to gain further insight into Gemini's capability for resolution of inflammation, Revelation tested samples from the Phase 1 clinical study. It was found that Gemini induced statistically significant, dose dependent changes in circulatory IL-10 at 2 hours post-dose, with a p-value of &lt; 0.05 or greater, at each of the low, mid, and high dose levels, as shown in Figure 1. The change in IL-10 observed for treatment groups relative to placebo, were a 27-fold increase, 162-fold increase, and 309-fold increase for the low, mid, and high dose groups, respectively.
IL-10 is a potent anti-inflammatory protein that downregulates pro-inflammatory cytokines and is an active contributor to initiating reduction of inflammation. The significant increase of anti-inflammatory IL-10 with no significant increase in pro-inflammatory IL-1β and TNF-α confirms TLR4 binding unique to Gemini, and is further evidence of the reprogramming of the innate immune response, enabling Gemini to initiate resolution of inflammation and promote the healing process.
The observed increase of IL-10 in humans is consistent with prior preclinical studies performed by Revelation where an increase in IL-10 was observed in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews60&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=healthy+animals&amp;index=2&amp;md5=dba735604f9f7922b050fc373a1fd8dd">healthy animals</a> as well as efficacy models, including the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstatic1.squarespace.com%2Fstatic%2F5f536d50b94bfb444769fc95%2Ft%2F65f114641526fa578482eaac%2F1710298213540%2FPrevention%2Bof%2BAKI%2Bw%2BGemini%2BCRRT%2BPresentation%2Band%2BPoster%2B2024.pdf&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=ischemia%2Freperfusion+model+of+acute+kidney+injury&amp;index=3&amp;md5=9a89ab3850d72e11e309d58197a508fc">ischemia/reperfusion model of acute kidney injury</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.revbiosciences.com%2Fnews48&amp;esheet=54126274&amp;newsitemid=20240924064564&amp;lan=en-US&amp;anchor=unilateral+ureteral+obstruction+model+of+kidney+injury&amp;index=4&amp;md5=c3be07701ccf2cae5a96619526bd4589">unilateral ureteral obstruction model of kidney injury</a>. This demonstrates the potential for Gemini in our target indications, including prevention of AKI following cardiac surgery.

REVB

Revelation Biosciences Observes IL-10 Increase in Phase 1 Gemini Trial

Keybanc analyst Jason Celino initiates coverage on Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Overweight rating and announces Price Target of $70.

Keybanc Initiates Coverage On Dayforce with Overweight Rating, Announces Price Target of $70

KBR was awarded this contract under the Department of Defense Information Analysis Center&#39;s (DoDIAC) multiple-award contract (MAC) vehicle. These IAC MAC task orders (TOs) are awarded by the U.S. Air Force&#39;s 774th Enterprise Sourcing Squadron to develop and create new knowledge for the enhancement of the DTIC repository and the R&amp;D and S&amp;T community.

Contracts

KBR Bags Estimated $113M Task Order To Perform Aeronautical Systems Research, Development, Test And Evaluation For AFLCMC/WL At Wright-Patterson Air Force Base, Ohio Over 5 Years

Nuvve Holding Corp. ("Nuvve") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>), a global technology leader accelerating the electrification of transportation through its proprietary energy management and aggregation platform, is proud to announce the commissioning of its first deployment in New Mexico in collaboration with Las Cruces Public Schools. This project marks a significant milestone in expanding electric vehicle infrastructure within the educational sector.
&nbsp;
Las Cruces Public Schools, the second largest school district in New Mexico, engaged Nuvve to deploy 5 Vehicle-to-Grid (V2G)-capable DC Fast Chargers and 7 Nuvve Level II PowerPorts, aimed at supporting the school district's transition to electric school buses and other electric vehicles. Gregory Poilasne, CEO of Nuvve, states, "We're thrilled to partner with Las Cruces Public Schools, a trailblazer amongst New Mexico's school districts, on this groundbreaking project in New Mexico. This collaboration exemplifies our mission to support the electrification of transportation within educational institutions, fostering a greener future for our children. By integrating our advanced charging solutions, we're not only reducing emissions but also creating significant energy savings for the district with future V2G revenues."
Daoud Chaaya, Thomas Built Buses VP-Sales, Aftermarket and Marketing, shares, "This project represents the first commissioned Nuvve chargers with Thomas buses in the state of New Mexico. The success of this deployment will pave the way for broader adoption of electric school buses across the state, showcasing the reliability and efficiency of Nuvve's technology and the best-in-class features of our Thomas Jouley school bus."
Ignacio Ruiz, superintendent of Las Cruces Public Schools adds, "Our partnership with Nuvve reflects our shared commitment to sustainability and innovation. By transitioning to electric vehicles and leveraging Nuvve's advanced energy management solutions, we are taking important steps towards reducing environmental impacts. This collaboration aims to not only address climate change but also to create a healthier environment for our students."

NVVE

Nuvve and Las Cruces Schools Launch First Electric Bus Charging Project in New Mexico

HSBC analyst Charlene Liu downgrades Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) from Buy to Hold and announces $100 price target.

Downgrades

BIDU

HSBC Downgrades Baidu to Hold, Announces $100 Price Target

SCKT

Socket Mobile Says CaptureSDK And Its Entire Line Of Barcode Scanners And NFC Reader/Writers Have Been Thoroughly Tested And Have Achieved Full Compatibility With iOS 18

In Georgia, the company is collaborating with Kelly Family Distributor, the premier distributor for Black-owned wine and spirits brands, ensuring a robust foothold in the local market.

LiveOne Partners With SOKO, California's First Black-owned And Woman-owned Distributor, To Enhance Its Presence In California

TD Cowen analyst Tara Bancroft initiates coverage on Protagonist Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>) with a Buy rating and announces Price Target of $65.

PTGX

TD Cowen Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $65

Needham analyst Scott Berg reiterates Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) with a Buy and maintains $70 price target.

Reiteration

BRZE

Needham Reiterates Buy on Braze, Maintains $70 Price Target

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a &#8220;miracle&#8221; weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
What Happened: Jorgensen is scheduled to testify before a <a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on">Senate committee on Tuesday</a> to discuss U.S. pricing for Ozempic and the weight loss drug Wegovy. The comments align with Wall Street analysts&#8217; expectations that Ozempic will be on the 2027 price negotiation list, which will be announced in February 2025, Reuters reported.
Last week, another Novo executive indicated that Ozempic would &#8220;very likely&#8221; be included in the 2027 list. A month&#8217;s supply of Ozempic currently lists at $935.77 in the U.S., while Wegovy lists for $1,349.02 per month, although insurance often reduces these costs.
The Inflation Reduction Act of 2022 permits Medicare to negotiate prices for costly prescription drugs, impacting millions of Americans. Both Ozempic and Wegovy have faced scrutiny from lawmakers over their high prices in the U.S.
Jorgensen noted that the net price of Ozempic has decreased by about 40% since its U.S. introduction, and Wegovy&#8217;s net price has similarly declined since its launch. He expects net prices for both drugs to continue to fall under current market conditions.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40989263/long-term-medical-cannabis-use-has-no-significant-harmful-effects-on-memory-or-impulse-control-n?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Long-Term Medical Cannabis Use Has No Significant Harmful Effects On Memory Or Impulse Control, New Study</a>
Why It Matters: The upcoming Senate hearing, scheduled for Tuesday, will see Lars Fruergaard Jorgensen face rigorous questioning from U.S. lawmakers regarding the high prices of Ozempic and Wegovy. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor, and Pensions, has been vocal about the exorbitant costs of these medications.
In a previous interview, Jorgensen <a href="https://www.benzinga.com/general/biotech/24/08/40550961/novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-">defended the high U.S. prices</a>, arguing that these drugs help reduce the economic burden of obesity-related health issues, which costs the U.S. over $400 billion annually. He dismissed accusations that Novo Nordisk operates as a drug cartel as &#8220;unfounded.&#8221; 
Additionally, the issue of counterfeit Ozempic has emerged as a significant concern. Criminals have been <a href="https://www.benzinga.com/general/biotech/24/09/40737027/fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern">distributing fake versions</a> of the drug by forging batch numbers, which has become an international issue. The World Health Organization and Interpol have both issued warnings about these counterfeit products. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40962322/corbus-pharma-crbp-stock-drops-60-after-novo-nordisks-cannabinoid-based-weight-loss-drug-trial-d?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Novo Nordisk And Corbus Pharmaceutical Stocks Plummet</a></li>
</ul>
Photo via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Biotech

Health Care

General

'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing

Bank of Japan Governor Kazuo Ueda indicated on Tuesday that the central bank is in no hurry to raise interest rates further.
What Happened: Ueda mentioned that the BOJ will closely monitor financial markets and global economic conditions before making any decisions, Reuters reported. 
He emphasized the importance of analyzing October&#8217;s service-price data, which will be available in November, to determine if underlying inflation is moving towards the BOJ&#8217;s 2% target.
During a news conference in Osaka, Ueda highlighted the need to scrutinize actual data before making any rate hike decisions, suggesting that the BOJ will wait until at least December. 
The next policy meeting is scheduled for Oct. 30-31, where a quarterly review of growth and inflation forecasts will also take place.
&#8220;We must conduct policy in a timely, appropriate fashion without having any pre-set schedule in mind, taking into account various uncertainties,&#8221; said Ueda.
Ueda reiterated that the BOJ would raise rates if underlying inflation accelerates towards the 2% target. However, he warned of risks such as volatile financial markets and uncertainty about the U.S. economy&#8217;s ability to achieve a soft landing.
He noted that the yen&#8217;s recent stabilization has reduced the risk of inflation overshooting due to rising import prices. Ueda stressed the importance of monitoring market developments and overseas economic conditions in setting monetary policy.
Ueda&#8217;s remarks reflect a shift in the BOJ&#8217;s focus from inflationary risks to concerns about slowing global growth and the impact of yen fluctuations on Japan&#8217;s export-driven economy, according to the report.
See Also: <a href="https://www.benzinga.com/markets/equities/24/09/40752387/treasury-yields-plunge-tlt-etf-tops-100-vix-spikes-as-50-basis-point-rate-cut-odds-soar-in-respo?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Treasury Yields Plunge, TLT ETF Tops $100, VIX Spikes As 50-Basis-Point Rate Cut Odds Soar In Response To Jobs Data</a>
Why It Matters: The Bank of Japan has been a significant outlier in the global monetary landscape, maintaining its interest rate at 0.25% while other major central banks have been cutting rates to counteract slowing inflation. 
On Thursday, the BOJ decided to keep its <a href="https://www.benzinga.com/markets/asia/24/09/40951221/bank-of-japan-leaves-interest-rate-at-0-25-diverging-from-feds-50-basis-point-cut">benchmark rate unchanged</a>, diverging from the Federal Reserve&#8217;s 50 basis point cut.
This decision aligns with predictions from a Reuters poll, where economists anticipated another <a href="https://www.benzinga.com/markets/asia/24/09/40842879/major-central-banks-slash-rates-in-sync-but-one-holdout-threatens-to-derail-bulls-momentum-carry-tra">rate hike by the end of the year</a>. 
Meanwhile, other global central banks, including the People&#8217;s Bank of China, have been cutting rates and injecting liquidity to <a href="https://www.benzinga.com/markets/asia/24/09/40974460/chinas-central-bank-follows-feds-dovish-move-cuts-key-short-term-rates-injects-over-10b-to-boost-eco">support their economies</a>. China&#8217;s central bank recently reduced a key short-term interest rate and injected over $10 billion into the financial system to boost economic growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40931458/obama-era-economist-says-she-is-pleasantly-surprised-that-jd-vance-thinks-the-economy-is-too-strong?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Obama-Era Economist Says She Is &#8216;Pleasantly Surprised&#8217; That JD Vance Thinks The &#8216;Economy Is Too Strong For The Rate Cut&#8217;</a></li>
</ul>
Image Via Shutterstock 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Asia

Economics

Markets

Bank of Japan Governor Takes Cautious Stance On Interest Rates, Awaiting Key Economic Data Amid Global Uncertainty

Needham analyst Laura Martin reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Buy and maintains $260 price target.

AAPL

Needham Reiterates Buy on Apple, Maintains $260 Price Target

TotalEnergies SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) shares are trading higher premarket Tuesday. The company inked a Heads of Agreement (HoA) with HD Hyundai Chemical to deliver 200,000 tons of liquefied natural gas (LNG) per year for <a target="_blank" href="https://totalenergies.com/news/press-releases/south-korea-totalEnergies-will-supply-200-000-tons-per-year-of-lng-to-hd-hyundai-chemical-until-2033" rel="noreferrer noopener">seven </a>years starting in 2027.
This agreement aligns with TotalEnergies&#8217; strategy to expand its long-term LNG sales and reinforces its position in South Korea, the third-largest LNG importer globally.
The pricing under the deal will be indexed to both Brent crude oil and the Henry Hub natural gas benchmark.
Gregory Joffroy, Senior Vice President, LNG at TotalEnergies, said, &#8220;We are pleased with this agreement with HD Hyundai Chemical, which will supply natural gas to one of their industrial sites. This agreement allows us to continue securing long-term sales in Asia and reduce our exposure to spot market gas prices.&#8221;
Yesterday, TotalEnergies signed a 10-year agreement to supply Air France-KLM with 1.5 million tons of <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40976214/totalenergies-and-air-france-klm-double-down-on-sustainability-saf-deal-paves-the-way-to-carbon-" rel="noreferrer noopener">sustainable aviation fuel (SAF) through 2035</a>.
Last week, TotalEnergies extended its sales and purchase agreement (SPA) with&nbsp;CNOOC&nbsp;<a target="_blank" href="https://www.benzinga.com//node/40934542" rel="noreferrer noopener">by an additional five years</a>.
Investors can gain exposure to the stock via&nbsp;Advisor Managed Portfolios Miller Value Partners Appreciation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MVPA#NYSE">MVPA</a>) and&nbsp;Octane All-Cap Value Energy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTA#NASDAQ">OCTA</a>).
Price Action: TTE shares are up 0.32% at $69.39 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/40996232" target="_blank" rel="noreferrer noopener">S&amp;P Settles At Fresh Record High: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Equities

Large Cap

MVPA

OCTA

TotalEnergies Secures 7-Year LNG Deal With HD Hyundai Chemical: Expanding Reach In Asia's Energy Market

Needham analyst Ryan Koontz reiterates Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) with a Buy and maintains $50 price target.

CLFD

Needham Reiterates Buy on Clearfield, Maintains $50 Price Target

Shares of Maison Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) rose sharply in today's pre-market trading after the company reported a year-over-year increase in <a href="https://www.benzinga.com/quote/MSS/earnings">first-quarter sales results.</a>
Maison Solutions reported $29.60 million in sales this quarter, representing a 114.49% increase over sales of $13.80 million the same period last year.
Maison Solutions shares jumped 91.4% to $1.41 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Heart Test Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) gained 69.7% to $4.99 in the pre-market trading session.</li>
<li>Generations Bancorp NY, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBNY#NASDAQ">GBNY</a>) rose 47.3% to $16.87 in pre-market trading. ESL Federal Credit Union agreed to acquire substantially all assets and liabilities (including deposit account liabilities) of Generations Bank.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares rose 31% to $0.2598 in pre-market trading.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) gained 20.4% to $0.3497 in pre-market trading. The Oncology Institute recently said Mihir Shah, will transition out of the organization effective Oct. 14, to pursue other opportunities.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) rose 14.8% to $0.2888 in pre-market trading after gaining 18% on Monday.</li>
<li>flyExclusive, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYX#NASDAQ">FLYX</a>) gained 12.3% to $2.57 in pre-market trading after dipping 34% on Monday.</li>
<li>Forza X1, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRZA#NASDAQ">FRZA</a>) gained 9.2% to $0.28 in pre-market trading after falling around 7% on Monday.</li>
<li>Futu Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) shares gained 8.3% to $72.90 in pre-market trading.</li>
<li>Stitch Fix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) shares rose 5% to $3.98 in pre-market trading ahead of quarterly earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>BioVie Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) fell 52.4% to $1.34 in pre-market trading after the company raised $3 million via secondary stock offering of 1.96 million shares at $1.53 per share.</li>
<li>Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) shares dipped 17.1% to $93.43 in pre-market trading after the company received an order from the U.S. District Court for the District of Nevada granting Aristocrat a preliminary injunction relating to L&amp;W&#8217;s Dragon Train game..</li>
<li>Fresh2 Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares fell 16.5% to $1.52 in pre-market trading after gaining 5% on Monday.</li>
<li>Jeffs&#8217; Brands Ltd  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) shares declined 13.7% to $0.3274 in pre-market trading after jumping 35% on Monday.</li>
<li>Expion360 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) fell 12.6% to $0.1023 in pre-market trading following a 38% gain on Monday.</li>
<li>Kidpik Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIK#NASDAQ">PIK</a>) fell 12.3% to $2.00 in today's pre-market trading after jumping over 8% on Monday.</li>
<li>Orgenesis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares fell 11.8% to $0.34 in pre-market trading. Orgenesis shares dipped around 25% on Monday after the company announced a 1-for-10 reverse stock split.</li>
<li>Hawaiian Electric Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HE#NASDAQ">HE</a>) shares declined 10.5% to $9.75 in pre-market trading. Hawaiian Electric Industries raised $500 million via secondary stock offering of 54 million shares at $9.25 per share.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) declined 5.8% to $2.34 in pre-market trading. Uxin shares jumped 54% on Monday after the company reported a year-over-year increase in first-quarter sales results.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) shares fell 3.3% to $109.56 in pre-market trading after the company announced a $2 billion private placement of senior convertible notes.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

BIVI

FLYX

FRES

FRZA

FUTU

GBNY

HSCS

JFBR

MLGO

Merrill Lynch & Strategic Return Notes for Select 10 Index

NUKK

ORGS

SFIX

SNOW

UXIN

XPON

Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket

Odyssey Semiconductor names co-founder Rick Brown as CEO

Odyssey Semiconductor Tech (ODII) has released an update. Odyssey Semiconductor Technologies, Inc. has issued two secured convertible promissory no...

Odyssey Semiconductor Tech Secures Convertible Notes Financing

Odyssey Semiconductor Technologies reports Q4 results

Odyssey Semiconductor Tech (ODII) has issued an update. Odyssey Semiconductor Technologies, Inc. announced its fourth-quarter financial results for...

Odyssey Semiconductor Announces Q4 2023 Financial Results

Odyssey Semiconductor Tech (ODII) has provided an update. On March 13, 2024, a company announced the execution of an asset purchase agreement, aimi...

Odyssey Semiconductor Announces Strategic Asset Purchase Agreement

Power Integrations to acquire the assets of Odyssey Semiconductor

An update from Odyssey Semiconductor Tech (ODII) is now available. Odyssey Semiconductor Technologies has agreed to sell substantially all of its a...

Odyssey Semiconductor Announces Asset Sale and Approaching Dissolution

Odyssey Semiconductor Tech (ODII) has provided an announcement. Odyssey Semiconductor Technologies, Inc. has announced its plans to dissolve and li...

Odyssey Semiconductor Announces Dissolution and Asset Sale

Odyssey Semiconductor Tech (ODII) just unveiled an announcement. The company, in compliance with Delaware law, is set to continue operations for th...

Odyssey Semiconductor Tech Commences Liquidation Process

ODII

POWI

Earnings

Press Releases

Odyssey Semiconductor Technologies Reports Third Quarter 2023 Financial Results

Odyssey Semiconductor Technologies Announces CEO Transition

Odyssey Semiconductor Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

Odyssey Semiconductor Technologies Enters into Definitive Agreement to Sell Assets For $9.52 Million

Power Integrations to Acquire the Assets of Odyssey Semiconductor

Odyssey Semiconductor Technologies Announces Stockholder Approval of Asset Sale to Power Integration

Odyssey Semiconductor Technologies Announces Final Dissolution Date

Odyssey Semiconductor

Transaction supports continuing development of high-voltage, high-power GaN technologyPower Integrations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWI#NASDAQ">POWI</a>), the leader in high-voltage integrated circuits for energy-efficient power conversion, today announced an agreement to acquire the assets of Odyssey Semiconductor Technologies (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ODII#OTCQB">ODII</a>), a developer of vertical gallium-nitride (GaN) transistor technology. The transaction is expected to close in July 2024, after which all key Odyssey employees are expected to join Power Integrations' technology organization.The acquisition supports the company's ongoing development roadmap for its proprietary PowiGaN&#x2122; technology, which is featured in many of the company's product families including InnoSwitch&#x2122; ICs, HiperPFS&#x2122;-5 power-factor-correction ICs and the recently launched InnoMux&#x2122;-2 family of single-stage, multiple-output ICs. The company introduced 900- and 1250-volt versions of PowiGaN technology and products in 2023.Commented Dr. Radu Barsan, Power Integrations' vice president of technology: "Power Integrations has been at the forefront of GaN development and commercialization since we began shipping products with PowiGaN technology in 2018. We are executing on an ambitious roadmap that includes driving toward cost parity with silicon MOSFETs and expanding the voltage and power capabilities of PowiGaN. Our goal is to commercialize a cost-effective high-current and high-voltage GaN technology to support higher-power applications currently served by silicon carbide (SiC), at a much lower cost and higher performance enabled by the fundamental material advantages of GaN over SiC. The experience of the Odyssey team in high-current vertical GaN will augment and accelerate these efforts, and we are delighted to add them to our team."Added Dr. Richard Brown, Odyssey co-founder and CEO: "The Odyssey team and I are excited to join Power Integrations in accelerating their GaN technology roadmap. As the first company to commercialize high-voltage GaN, Power Integrations continues to lead the industry in driving the technology forward in terms of cost, voltage and current, as well as the design of system-level products that take full advantage of the capabilities of GaN."

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Odyssey Semiconductor

News

Latest news for Odyssey Semiconductor (OTC:ODII) Stock

Tuesday, May 07, 2024